Calcific aortic valve disease: can targeting endothelial-mesenchymal transition be a new alternative to surgery?-a narrative review - PubMed
12 hours ago
- #Endothelial-mesenchymal transition
- #Calcific aortic valve disease
- #Non-surgical therapy
- Calcific aortic valve disease (CAVD) is a progressive cardiovascular condition common in the elderly, leading to valve thickening, calcification, and stiffness.
- Current treatments like SAVR and TAVR are invasive, costly, and not suitable for early-stage or asymptomatic patients.
- Endothelial-mesenchymal transition (EndMT) plays a key role in CAVD pathogenesis by promoting fibrosis, inflammation, and osteogenic differentiation.
- Targeting EndMT-related pathways (TGF-β, Notch, Wnt) could offer non-surgical therapeutic options for CAVD.
- Combining EndMT-targeted therapies with anti-inflammatory and anti-calcification strategies may slow disease progression and reduce surgical reliance.
- Further research is needed to fully understand EndMT mechanisms and develop effective early-stage interventions for CAVD.